Current status of viral gene therapy for brain tumours

Bibliography

• ARAQUE A, PARPURA V, SANZGIRI RP, HAYDON PG: Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. (1999) 22(5)208–215.
   Google Scholar
• GONZALES MF: Classification and pathogenesis of brain tumors. In: Brain Tumours. AH Kaye, ER Laws, (Eds.), Churchill Livingstone, New York, USA (1995):31–45.
   Google Scholar
• HOSHINO T, AHN D, PRADOS MD, LAMBORN K, WILSON CB: Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int. J. Cancer (1993) 53(4)550–555.
   Google Scholar
• LEGLER JM, RIES LA, SMITH MA et al.: Cancer surveillance series: brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl. Cancer Inst. (1999) 91(16):1382–1390.
   PubMed Web of Science ®Google Scholar
• GILES GG, GONZALES MF: Epidemiology of brain tumors and factors in prognosis. In: Brain Tumours. Kaye AH, Laws ER (Eds.) Churchill Livingstone, New York (1995):47–67.
   Google Scholar
• LANG FF, MILLER DC, KOSLOW M, NEWCOMB EW: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg (1994) 81(3):427–436.
   PubMed Web of Science ®Google Scholar
• WATANABE K, TACHIBANA O, SATA K et al: Overexpres-sion of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. (1996) 6 (3) :217–223.
   PubMed Web of Science ®Google Scholar
• TOHMA Y, GRATAS C, BIERNAT W et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropa-thol. Exp. Neurol. (1998) 57(7):684–689.
   PubMed Web of Science ®Google Scholar
• BIERNAT W, KLEIHUES P, YONEKAWA Y, OHGAKI H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. (1997) 56(2):180–185.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER DR, ZAGZAG D, SHIFF B et al.: Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta! integrins. Cancer Res. (1996) 56(8):1939–1947.
   PubMed Web of Science ®Google Scholar
• COLLINS VP: Progression as exemplified by human astrocytic tumors. Semin. Cancer Biol. (1999) 9(4):267–276.
   PubMed Web of Science ®Google Scholar
• •A summary of multistep changes in astrocytic by the scientist who contributed the most to this area.
   Google Scholar
• HERMENS WT, VERHAAGEN J: Viral vectors, tools for gene transfer in the nervous system. Prog. Neurobiol (1998) 55 (4):399–432.
   PubMed Web of Science ®Google Scholar
• SPAETE RR, FRENKEL N: The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell (1982) 30(1):295–304.
   PubMed Web of Science ®Google Scholar
• ••A landmark paper describing how a human virus could bemodified to carry DNA of interest.
   Google Scholar
• ROIZMAN B, SEARS AE, Herpes simplex viruses and their replication.. In: The Human Herpesviruses. Roizman B, Whitley RJ, Lopez C (Eds.) Raven Press, New York, USA (1993):11–61.
   Google Scholar
• KWONG AD, KRUPER JA, FRENKEL N: Herpes simplex virus virion host shutoff function. J. Virology (1988) 62 (3) :912–921.
   PubMed Web of Science ®Google Scholar
• MACKEM S, ROIZMAN B: Differentiation between alpha promoter and regulator regions of herpes simplex virus 1: the functional domains and sequence of a movable alpha regulator. Proc. Natl. Acad. Sci. USA (1982) 79(16):4917–4921.
   PubMed Web of Science ®Google Scholar
• DOBSON AT, MARGOLIS TP, SEDARATI F, STEVENS JG, FELDMAN LT: A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons. Neuron (1990) 5(3):353–360.
   PubMed Web of Science ®Google Scholar
• JOHNSON PA, MIYANOHARA A, LEVINE F, CAHILL T, FRIEDMANN T: Cytotoxicity of a replication-defective mutant of herpes simplex virus Type 1. J. Vim]. (1992) 66(5)2952–2965.
   Google Scholar
• CHOU J, KERN ER, WHITLEY RJ, ROIZMAN B: Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science (1990) 250(4985):1262–1266.
   Google Scholar
• ••Molecular dissection of various genes leads to a gene thatmay be responsible for the neurotropism of herpes virus.
   Google Scholar
• CHOU J, ROIZMAN B: The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Nad Acad. Sci. USA (1992) 89(8):3266–3270.
   Google Scholar
• CHOU J, ROIZMAN B: Herpes simplex virus 1gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc. Nati Acad. Sci. USA (1994) 91 (12):5247–5251.
   Google Scholar
• CHAMBERS R, GILLESPIE GY, SOROCEANU L et al: Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA (1995) 92(5):1411–1415.
   PubMed Web of Science ®Google Scholar
• KESARI S, LEE VM, BROWN SM, TROJANOWSKI JQ, FRASER NW: Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1. J. Neurosci. (1 9 9 6) 16(18)5644–5653.
   Google Scholar
• KESARI S, RANDAZZO BP, VALYI-NAGY T et al: Therapy of experimental human brain tumors using a neuroat-tenuated herpes simplex virus mutant. Lab. Invest. (1995) 73(5):636–648.
   PubMed Web of Science ®Google Scholar
• GELLER Al, BREAKEFIELD XO: A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science (1 9 88) 241(4873)1667–1669.
   Google Scholar
• •A reporter gene is expressed by a HSV-1 vector, thereby demonstrating the principle that a foreign gene can be expressed by a viral vector in infected mammalian cells.
   Google Scholar
• FREINKEL N, SINGER O, KWONG RENKEL AD: Minire-view: the herpes simplex virus amplicon-a versatile defective virus vector. Gene Ther. (1994) 1 (Suppl. 1):S40–46.
   Google Scholar
• YONISH-ROUACH E, RESNITZKY D, LOTEM J. et al.: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 352(6333)345–347.
   Google Scholar
• GRAHAM FL, PREVEC L: Methods for construction of adenovirus vectors. Mol. Biotechnol. (1995) 3 (3):207–220.
   PubMed Web of Science ®Google Scholar
• DAVIDSON BL, ALLEN ED, KOZARSKY KF, WILSON JM, ROESSLER BJ: A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genet. (1993) 3(3):219–223.
   PubMed Web of Science ®Google Scholar
• •This paper describes the possibility of using adenovirus as a vector system in the CNS.
   Google Scholar
• AKLI S, CAILLAUD C, VIGNE E et al.: Transfer of a foreigngene into the brain using adenovirus vectors. Nature Genet. (1993) 3(3):224–228.
   PubMed Web of Science ®Google Scholar
• •See reference [29] for annotation.
   Google Scholar
• BAJOCCHI G, FELDMAN SH, CRYSTAL RG, MASTRANGELI A: Direct in vivogene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nature Genet. (1993) 3(3):229–234.
   PubMed Web of Science ®Google Scholar
• •See reference [29] for annotation.
   Google Scholar
• LA SALLE G, ROBERT JJ, BERRARD S et al.: An adenovirus vector for gene transfer into neurons and glia in the brain. Science (1993) 259(5097):988–990.
   PubMed Web of Science ®Google Scholar
• •See reference [29] for annotation.
   Google Scholar
• ZHANG Y, SCHNEIDER RJ: Adenovirus inhibition of celltranslation facilitates release of virus particles and enhances degradation of the cytokeratin network. J. Vim]: (1994) 68(4):2544–2555.
   Web of Science ®Google Scholar
• YANG Y, NUNES FA, BERENCSI K et al.: Cellularimmunity to viral antigens limits El-deleted adenovi-ruses for gene therapy. Proc. Nati Acad. Sci. USA (1994) 91 (104407–4411.
   Google Scholar
• ENGELHARDT JF, YE X, DORANZ B, WILSON JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA (1994) 91(13)6196–6200.
   Google Scholar
• WANG Q, JIA XC, FINER MH: A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. (1995) 2(10775–783.
   Google Scholar
• WANG Q, FINER MH: Second-generation adenovirus vectors. Nature Med. (1996) 2(6):714–716.
   PubMed Web of Science ®Google Scholar
• KROUGLIAK V, GRAHAM FL: Development of cell lines capable of complementing El, E4 and protein IX defective adenovirus Type 5 mutants. Hum. Gene Ther. (1995) 6(12):1575–1586.
   PubMed Web of Science ®Google Scholar
• PARKS RJ, CHEN L, ANTON M et al: A helper-dependentadenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA (1996) 93(24):13565–13570.
   PubMed Web of Science ®Google Scholar
• FISHER KJ, CHOI H, BURDA J, CHEN SJ, WILSON JM: Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology (1996) 217(0:11–22.
   PubMedGoogle Scholar
• LINDEN RM, BERNS KI: Site-specific integration by adeno-associated virus: a basis for a potential gene therapy vector [editorial]. Gene Ther. (1997) 4(1)4–5.
   Google Scholar
• LINDEN RM, WARD P, GIRAUD C, WINOCOUR E, BERNSKI: Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA (1996) 93(20:11288–11294.
   PubMedGoogle Scholar
• MUZYCZKA N: Use of adeno-associated virus as ageneral transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. (1992) 158:97–129.
   PubMed Web of Science ®Google Scholar
• WEITZMAN MD, KYOSTIO SR, KOTIN RM, OWENS RA: Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integra-tion site in human DNA. Proc. Natl. Acad. Sci. USA (1994) 91(13)5808–5812.
   Google Scholar
• BERNS KI: Parvovirus replication. Microbiol. Rev. (1990)54 (3):316–329.
   PubMedGoogle Scholar
• KEARNS WG, AFIONE SA, FULMER SB etal. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther. (1996) 3 (9) 748–755
   Google Scholar
• PONNAZHAGAN S, ERIKSON D, KEARNS WG et al. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum. Gene Ther. (1997) 8(3):275–284.
   PubMed Web of Science ®Google Scholar
• WU P, PHILLIPS MI, BUI J, TERWILLIGER EF: Adeno- associated virus vector-mediated transgene integra-tion into neurons and other nondividing cell targets. J. Virol. (1998) 72(7):5919–5926.
   PubMed Web of Science ®Google Scholar
• KAPLITT MG, LEONE P, SAMULSKI RJ et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet. (1994) 8(2):148–154.
   PubMed Web of Science ®Google Scholar
• LIEBER A, STEINWAERDER DS, CARLSON CA, KAY MA: Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J. Virol. (1999) 73(10:9314–9324.
   PubMedGoogle Scholar
• FISHER KJ, KELLEY WM, BURDA JF, WILSON JM: A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum. Gene Ther. (1996) 7(17):2079–2087.
   PubMed Web of Science ®Google Scholar
• JOHNSTON KM, JACOBY D, PECHAN PA et al.: HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. (1997) 8(3)359–370.
   Google Scholar
• ROBBINS PD, TAHARA H, MUELLER G et al: Retroviralvectors for use in human gene therapy for cancer, Gaucher disease and arthritis. Ann. NY Acad. Sci. (1994) 716:72–89.
   PubMed Web of Science ®Google Scholar
• MILLER AD, MILLER DG, GARCIA JV, LYNCH CM: Use of retroviral vectors for gene transfer and expression. Methods Enzymol. (1993) 217:581–599.
   PubMed Web of Science ®Google Scholar
• MILLER AD: Retrovirus packaging cells. Hum. Gene Ther. (1990) 1(0:5–14.
   PubMedGoogle Scholar
• RAINOV NG, KRAMM CM, ABOODY-GUTERMAN K et al.:Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther. (1996) 3(2):99–106.
   PubMed Web of Science ®Google Scholar
• KAFRI T, BLOMER U, PETERSON DA, GAGE FH, VERMAIM: Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genet. (1997) 17(3):314–317.
   PubMed Web of Science ®Google Scholar
• MIYOSHI H, TAKAHASHI M, GAGE FH, VERMA IM: Stableand efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Nati Acad. Sci. USA (1997) 94(19):10319–10323.
   PubMed Web of Science ®Google Scholar
• REISER J, HARMISON G, KLUEPFEL-STAHL S et al.: Transduction of nondividing cells using pseudotyped defective high-titer HIV Type 1 particles. Proc. Natl. Acad. Sci. USA (1996) 93(26):15266–15271.
   PubMed Web of Science ®Google Scholar
• NALDINI L, BLOMER U, GALLAY P et al: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272(5259):263–267.
   PubMed Web of Science ®Google Scholar
• PAULUS W, BAUR I, BOYCE FM, BREAKEFIELD XO, REEVES SA: Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. Vim]. (1996) 70(1):62–67.
   Web of Science ®Google Scholar
• MOOLTEN FL, WELLS JM, HEYMAN RA, EVANS RM: Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum. Gene Ther. (1990) 1 (2): 125–134.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL, WELLS JM: Curability of tumors bearingherpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. (1990) 82 (4):297–300.
   PubMed Web of Science ®Google Scholar
• EZZEDDINE ZD, MARTUZA RL, PLATIKA D et al.: Selectivekilling of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. (1991) 3(6):608–614.
   PubMedGoogle Scholar
• •One of the first papers to illustrate the use of the HSV-tk system to kill glioma cells.
   Google Scholar
• TAKAMIYA Y, SHORT MP, EZZEDDINE ZD et al.: Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus Type 1-thymidine kinase gene and wild type retrovirus kills oTher. tumor cells. J. Neuroscience Res. (1992) 33(3):493–503.
   PubMed Web of Science ®Google Scholar
• TAKAMIYA Y, SHORT MP, MOOLTEN FL et al.: An experi-mental model of retrovirus gene therapy for malignant brain tumors. J. Neurosurg. (1993) 79 (1):104–110.
   PubMed Web of Science ®Google Scholar
• CULVER KW, RAM Z, WALLBRIDGE S et al.: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 256(5063):1550–1552.
   PubMed Web of Science ®Google Scholar
• ••Regression of brain tumours in a murine model occurs afteruse of retroviruses.
   Google Scholar
• VINCENT AJ, VOGELS R, SOMEREN GV et al: Herpessimplex virus thymidine kinase gene therapy for rat malignant brain tumors. Hum. Gene Ther. (1996) 7(2):197–205.
   PubMed Web of Science ®Google Scholar
• ECK SL, ALAVI JB, ALAVI A et al.: Treatment of advancedCNS malignancies with the recombinant adenovirus 115.01ORSVTK: a Phase I trial. Hum. Gene Ther. (1996) 7(12):1465–1482.
   Google Scholar
• •This Phase I trial and others (see Kun et al. [92]) demonstrated the safety of viral vectors to treat malignant tumors. The effectiveness of these first vectors is unclear and awaits future Phase III trials.
   Google Scholar
• KLATZMANN D, VALERY CA, BENSIMON G et al: A PhaseI/II study of herpes simplex virus Type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblas-toma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. (1998) 9(17):2595–2604.
   PubMed Web of Science ®Google Scholar
• CULVER KW: Gene therapy for malignant neoplasms ofthe CNS. Bone Marrow Transplant. (1996) 18(3):S6–9.
   Google Scholar
• MESNIL M, PICCOLI C, TIRABY G, WILLECKE K, YAMASAKI H: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA (1996) 93 (5): 1831–1835.
   PubMed Web of Science ®Google Scholar
• DILBER MS, ABEDI MR, CHRISTENSSON B et al.: Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. (1997) 57(8):1523–1528.
   PubMed Web of Science ®Google Scholar
• ESTIN D, LI M, SPRAY D, WU JK: Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery (1999) 44 (2):361–369.
   PubMed Web of Science ®Google Scholar
• CAIRNCROSS JG, UEKI K, ZLATESCU MC et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendro-gliomas. J. Natl. Cancer Inst. (1998) 90(19):1473–1479.
   PubMed Web of Science ®Google Scholar
• FULCI G, ISHII N, VAN MEIR EG: p53 and brain tumors: from gene mutations to gene therapy. Brain Pathol. (1998) 8(4):599–613.
   PubMed Web of Science ®Google Scholar
• SANTARIUS T, KIRSCH M, ROSSI ML, BLACK PM: Molecular aspects of neuro-oncology. Clin. Neurol. Neurosurg. (1997) 99(3):184–195.
   PubMed Web of Science ®Google Scholar
• HAHN WC, COUNTER CM, LUNDBERG AS et al.: Creation of human tumour cells with defined genetic elements. Nature (1999) 400(6743):464–468.
   PubMed Web of Science ®Google Scholar
• BADIE B, DRAZAN KE, KRAMAR MH, SHAKED A, BLACK KL: Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol. Res. (1995) 17(3) :209–216.
   PubMed Web of Science ®Google Scholar
• ROSENFELD MR, MENESES P, DALMAU J. et al.: Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. Neurology (1995) 45(8):1533–1539.
   Google Scholar
• WEN DY, HALL WA, CONRAD J. et al.: Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol. Res. (1995) 17(3):209–216.
   Google Scholar
• BADIE B, KRAMAR MH, LAU R et al.: Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J. Neurooncol. (1998) 37(3):217–222.
   PubMed Web of Science ®Google Scholar
• LANG FF, YUNG WK, RAJU U et al.: Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J. Neurosurg. (1998) 89(0:125–132.
   PubMedGoogle Scholar
• SWISHER SG, ROTH JA, NEMUNAITIS J et al.: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (1999) 91(9)763–771.
   Google Scholar
• RILEY DJ, NIKITIN AY, LEE WH: Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/- mice. Nature Med. (1996) 2(12):1316–1321.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA R, CHENG SY, NAGASHIMA R et al.: Expres-sion of vascular endothelial growth factor in human brain tumors. Acta Neuropathol. (Berl) (1998) 96(5)453–462.
   Google Scholar
• HOLASH J, WIEGAND SJ, YANCOPOULOS GD: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene (1999) 18(38)5356–5362.
   Google Scholar
• VEIKKOLA T, ALITALO K: VEGFs, receptors and angiogenesis. Semin. Cancer Biol. (1999) 9 (3):211–220.
   PubMed Web of Science ®Google Scholar
• NEUFELD G, COHEN T, GENGRINOVITCH S, POLTORAKZ: Vascular endothelial growth factor (VEGF) and its receptors. Faseb. J. (1999) 13(0:9–22.
   PubMedGoogle Scholar
• MILLAUER B, SHAWVER LK, PLATE KH, RISAU W, ULLRICH A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 367(6463)576–579.
   Google Scholar
• MACHEIN MR, RISAU W, PLATE KH: Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum. Gene Ther. (1999) 10(7):1117–1128.
   PubMed Web of Science ®Google Scholar
• KUN LE, GAJJAR A, MUHLBAUER M et al.: Stereotacticinjection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum. Gene Ther. (1995) 6(9):1231–55.
   Google Scholar
• PACKER RJ, RAFFEL C, VILLABLANCA JG et al. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. (2000) 92 (2) 249–54
   PubMed Web of Science ®Google Scholar
• RAM Z, CULVER KW, OSHIRO EM et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med. (1997) 3 (12) 1354–1361.
   PubMed Web of Science ®Google Scholar